# CamTac Trial:Campath-Tacrolimus vs IL2R MoAb/Tacrolimus/MMF in Renal Transplantation

> **NCT00246129** · PHASE4 · COMPLETED · sponsor: **EMagnusson** · enrollment: 123 (actual)

## Conditions studied

- Kidney Transplantation
- Kidney Diseases
- Kidney Failure

## Interventions

- **DRUG:** Campath
- **DRUG:** Daclizumab

## Key facts

- **NCT ID:** NCT00246129
- **Lead sponsor:** EMagnusson
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 123 (ACTUAL)
- **Last updated:** 2021-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00246129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00246129, "CamTac Trial:Campath-Tacrolimus vs IL2R MoAb/Tacrolimus/MMF in Renal Transplantation". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00246129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*